<DOC>
	<DOCNO>NCT01523041</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare two formulation biphasic insulin aspart 70 characterise pharmacokinetics biphasic insulin aspart 50 biphasic insulin aspart 70 healthy male subject .</brief_summary>
	<brief_title>Comparison Two Formulations Biphasic Insulin Aspart 70</brief_title>
	<detailed_description>Each subject participate three treatment period , randomly assign six treatment sequence vary order</detailed_description>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Caucasian Considered generally healthy upon completion medical history physical examination judge Investigator Body mass index ( BMI ) 1927 kg/m^2 Fasting plasma glucose 3.86.0 mmol/L Participation clinical trial involve investigational product within last three month Clinically significant abnormal haematology biochemistry screen test , judge Investigator Any serious systemic infectious disease occur 4 week prior first dose test drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>